{'fraction_non_alphanumeric': 0.023485784919653894, 'fraction_numerical': 0.016069221260815822, 'mean_word_length': 5.694214876033058, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ROLE OF ALLELIC VARIANTS OF FK506‐BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS

Anxiety disorders exhibit remarkably high rates of comorbidity with major depressive disorder (MDD). Mood and anxiety disorders are considered stress‐related diseases. Genetic variations in the co‐chaperone FK506‐binding protein 51, FKBP5, which modulates the function of glucocorticoid receptors, have been associated with an increased risk for the development of posttraumatic stress disorder, but data regarding its role in MDD are controversial. The aims of this study were to clarify the role of the FKBP5 gene in depression and anxiety disorders through a case–control study and an association study with personality traits using the Temperament and Character Inventory (TCI) in healthy subjects.